Claims for Patent: 5,900,406

Summary for Patent: 5,900,406

Title:	Use of antibiotics of the type 2-deoxystreptamine substituted with aminosugars to inhibit growth of microorganisms containing group I introns
Abstract:	The invention described herein provides for methods of screening for compounds that can be used to prevent or inhibit the growth of microbial eukaryotes, particularly plant or animal pathogens. The screening methods of the invention involve the step of screening compounds for the ability to inhibit Group I intron I splicing. In addition, to directly screening for compounds that inhibit Group I intron splicing, the screening methods of the invention include screening for compounds that bind to prokaryotic 16S ribosomal RNA because of the correlation, described herein, between group I intron inhibition and binding to prokaryotic 16S ribosomal RNA. The range of possible compounds for screening by the screening methods of the invention is preferably limited to 2-deoxystreptamine derivatives. Another aspect of the invention is to provide methods of treating or preventing infections with eukaryotic microbes by administering an effective amount of a compound that inhibits group I intron splicing. These compounds may be obtained by the screening methods of the invention.
Inventor(s):	von Ahsen; Uwe (Santa Cruz, CA), Davies; Julian E. (Vancouver, CA), Schroeder; Renee (Vienna, AT)
Assignee:	NZYM, Inc. (San Leandro, CA)
Application Number:	08/255,611
Patent Claims:	1. A method for inhibiting a eukaryotic microbial infection in a subject, comprising administering an effective amount of an aminoglycoside to the subject. 2. The method of claim 1 in which the eukaryotic microbe contains a group I intron. 3. The method of claim 1 in which the eukaryotic microbe is a fungus. 4. The method of claim 1 in which the hexose nucleus of the aminoglycoside is 2-deoxystreptamine. 5. The method of claim 4 in which the amino sugar substitutions are at positions 4 and 5. 6. The method of claim 4 in which the amino sugar substitutions are at positions 4 and 6. 7. The method of claim 1 in which the aminoglycoside is selected from the group consisting of gentamicin C.sub.la, gentamicin C.sub.2, gentamicin C.sub.1, gentamicin B, G418, tobramycin, kanamycin A, kanamycin B, kanamycin C, neamine, ribostamycin, neomycin B, paromomycin B, sisomicin, 5-epi-sisomicin, dihydrosisomicin, and 1-N-acetyl-sisomicin. 8. A method for inhibiting growth of a eukaryotic microbe, comprising contacting the microbe with an aminoglycoside. 9. The method of claim 8 in which the eukaryotic microbe contains a group I intron. 10. The method of claim 8 in which the eukaryotic microbe is a fungus. 11. The method of claim 8 in which the hexose nucleus of the aminoglycoside is 2-deoxystreptamine. 12. The method of claim 11 in which the amino sugar substitutions are at positions 4 and 5. 13. The method of claim 11 in which the amino sugar substitutions are at positions 4 and 6. 14. The method of claim 8 in which the aminoglycoside is selected from the group consisting of gentamicin C.sub.la, gentamicin C.sub.2, gentamicin C.sub.1, gentamicin B, G418, tobramycin, kanamycin A, kanamycin B, kanamycin C, neamine, ribostamycin, neomycin B, paromomycin B, sisomicin, 5-epi-sisomicin, dihydrosisomicin, and 1-N-acetyl-sisomicin.

Details for Patent 5,900,406

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-05-04
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-05-04
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-05-04